Identifying homogeneous healthcare use profiles and treatment sequences by combining sequence pattern mining with care trajectory clustering in kidney cancer patients on oral anticancer drugs: A case study

被引:2
作者
Baudrier, Cyril [1 ]
Tran, Yohann [2 ]
Delanoy, Nicolas [3 ]
Katsahian, Sandrine [4 ,5 ,6 ]
Sabatier, Brigitte [1 ,5 ,6 ]
Perrin, Germain [1 ,5 ,6 ]
机构
[1] Hosp European Georges Pompidou, Pharm Dept, Paris, France
[2] Hosp European Georges Pompidou, Clin Res Dept, Paris, France
[3] Hosp European Georges Pompidou, Oncol Dept, Paris, France
[4] Hosp European Georges Pompidou, Clin Res Dept, Paris, France
[5] INSERM, Cordeliers Res Ctr, Paris, France
[6] INRIA, HeKA, Paris, France
关键词
Antineoplastic agents; cluster analysis; data mining; kidney neoplasms; patient care management; prognosis; sequential pattern mining; RENAL-CELL CARCINOMA; GUIDELINES; CONTINUITY;
D O I
10.1177/14604582221101526
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective We evaluated the ability of a coupled pattern-mining and clustering method to identify homogeneous groups of subjects in terms of healthcare resource use, prognosis and treatment sequences, in renal cancer patients beginning oral anticancer treatment. Methods Data were retrieved from the permanent sample of the French medico-administrative database. We applied the CP-SPAM algorithm for pattern mining to healthcare use sequences, followed by hierarchical clustering on principal components (HCPC). Results and conclusion We identified 127 individuals with renal cancer with a first reimbursement of an oral anticancer drug between 2010 and 2017. Clustering identified three groups of subjects, and discrimination between these groups was good. These clusters differed significantly in terms of mortality at six and 12 months, and medical follow-up profile (predominantly outpatient or inpatient care, biological monitoring, reimbursement of supportive care drugs). This case study highlights the potential utility of applying sequence-mining algorithms to a large range of healthcare reimbursement data, to identify groups of subjects homogeneous in terms of their care pathways and medical behaviors.
引用
收藏
页数:18
相关论文
共 32 条
  • [1] Tyrosine Kinase Inhibitor-Induced Hypertension
    Agarwal, Megha
    Thareja, Nidhi
    Benjamin, Melody
    Akhondi, Andre
    Mitchell, George D.
    [J]. CURRENT ONCOLOGY REPORTS, 2018, 20 (08)
  • [2] Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma
    Ambavane, Apoorva
    Yang, Shuo
    Atkins, Michael B.
    Rao, Sumati
    Shah, Anshul
    Regan, Meredith M.
    McDermott, David F.
    Michaelson, M. Dror
    [J]. IMMUNOTHERAPY, 2020, 12 (01) : 37 - 51
  • [3] [Anonymous], ALD N 30 CANC REIN L
  • [4] [Anonymous], HCPC HIERARCHICAL CL
  • [5] [Anonymous], Le Plan cancer 2014-2019-Les Plans cancer
  • [6] [Anonymous], Suivi des patients atteints de cancer: les generalistes favorables a des echanges renforces avec l'hopital/Direction de la recherche, des etudes, de l'evaluation et des statistiques Internet
  • [7] [Anonymous], 2020, INDICATEURS OBSERVAN
  • [8] [Anonymous], CANCERS REIN VIVRE A
  • [9] [Anonymous], PR SENTATION PROJET
  • [10] The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
    Bedke, Jens
    Albiges, Laurence
    Capitanio, Umberto
    Giles, Rachel H.
    Hora, Milan
    Lam, Thomas B.
    Ljungberg, Borje
    Marconi, Lorenzo
    Klatte, Tobias
    Volpe, Alessandro
    Abu-Ghanem, Yasmin
    Dabestani, Saeed
    Pello, Sergio Fernandez
    Hofmann, Fabian
    Kuusk, Teele
    Tahbaz, Rana
    Powles, Thomas
    Bex, Axel
    [J]. EUROPEAN UROLOGY, 2021, 80 (04) : 393 - 397